- Adjuvant hormone therapy in young women with early breast cancer in 20232023 | Publication without faculty affiliation
- Renální toxicita cílené léčby v onkologii2023 | First Faculty of Medicine
- Inhibitory CDK4/6 mění léčebnou praxi u pokročilého karcinomu prsu2017 | First Faculty of Medicine
- Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis2013 | Central Library of Charles University, First Faculty of Medicine
- Successful treatment of metastatic breast tumor using ribociclib in combination with hormonal therapy – case report2023 | Faculty of Medicine in Hradec Králové
- Palbociclib - a new dimension in palliative therapy of breast cancer2017 | First Faculty of Medicine
- Ribociclib2018 | First Faculty of Medicine
- Hormonální rezistence u karcinomu prsu a terapie CDK4/6 inhibitory - kazuistika pacientky se sekundární hormonální rezistencí na terapii abemaciclib s fulvestrantem2022 | First Faculty of Medicine
- Alpelisib v léčbě pacientky s karcinomem prsu - kazuistika2022 | First Faculty of Medicine
- Cyclin-dependent kinases - a suitable target in metastatic breast cancer2021 | First Faculty of Medicine
- Pleural mesothelioma2023 | Third Faculty of Medicine
- Strategies for managing endocrine resistance in advanced hormone receptor-positive and HER2-negative breast cancer2017 | First Faculty of Medicine
- Alpelisib - the first PI3K inhibitor in the treatment of hormone-positive, HER2-negative breast cancer2021 | First Faculty of Medicine
- CDK4/6 inhibitors in adjuvant therapy of breast cancer2023 | First Faculty of Medicine